

ONLINE SUPPLEMENTARY DATA

Supplementary Table 1. Comparison of extend of fibrosis on HRCT between systemic sclerosis groups stratified by antibody status

	Total	RNAP	ACA	ATA	Other Ab	No Ab	p-Value ^a	p- ^I value ^b
Patients, n (%)	279	33 (12)	134 (48)	46 (16)	55 (20)	11 (4)		
Baseline lung fibrosis, % mean (SD)	6.5 (12.4)	4.9 (7.6)	1.4 (4.0)	16.5	10.7 (13.6)	5.8 (8.9)	0.001	0.020
Follow up lung fibrosis, % mean (SD)	8.1 (14.1)	8.2 (10.6)	1.7 (4.5)	18.8	13.7 (16.7)	6.9 (10.5)	0.011	<0.001
Annual fibrosis progression, % mean (SD)	0.4 (2.2)	0.6 (1.6)	0.1 (0.7)	0.4 (4.3)	1.1 (2.7)	0.2 (0.4)	0.767	0.090
Fibrosis progression <20% to >20%, n (%)	11 (4.1)	4 (12.5)	1 (0.8)	2 (4.4)	2 (3.6)	1 (9.1)	0.197	0.007
1-20% fibrosis at follow up, n (%)	64 (23.2)	11 (33.3)	19 (14.2)	15 (32.6)	13 (23.6)	1 (9.1)	0.328	0.003
>20% fibrosis at follow up, n (%)	40 (14.5)	6 (18.2)	2 (1.5)	16 (34.8)	14 (25.5)	2 (18.2)	0.045	<0.001

RNAP: RNA Polymerase III, ACA: anti-centromere antibody; ATA: anti-Topoisomerase I; Ab: antibody; ^ap-values between RNAP and ATA; ^b: p-values between RNAP and ACA; n: number; SD: standard deviation

Supplementary Table 2. Comparison of pulmonary function between systemic sclerosis groups stratified by antibody status

	Total cohort	RNAP	ACA	ATA	Other Ab	No Ab	p-value ^a	p-value ^b
Patients, no (%)	279	33 (12)	134 (48)	46 (16)	55 (20)	11 (4)		
Baseline FVC, % mean (SD)	94.4 (20.4)	88.8 (20.6)	102.4 (18.9)	82.2 (20.2)	89.6 (17.3)	88.8 (16.2)	0.163	<0.001
Follow up FVC, % mean (SD)	98.3 (23.4)	83.2 (21.6)	98.4 (21.8)	75.7 (23.3)	84.9 (20.6)	78.3(19.9)	0.155	0.001
FVC <70% at follow up, n (%)	53 (19)	8 (24)	9 (7)	17 (37)	15 (27.3)	4 (36.4)	0.238	0.003
FVC <80% at follow up, n (%)	84 (30.4)	13 (39.4)	18 (13.4)	26 (46.5)	19 (34.5)	8 (72.7)	0.138	0.001
Baseline DLCO, % mean (SD)	67.9 (21.3)	66.1 (21.3)	71.5 (22.3)	64.4 (19.2)	65.9 (20.8)	56.6 (15.9)	0.718	0.214
Follow up DLCO, % mean (SD)	59.2 (20.7)	59.3 (20.7)	61.7 (21.2)	57.2 (20.1)	56.3 (21.3)	49.7 (21.8)	0.667	0.541

RNAP: RNA Polymerase III, ACA: anti-centromere antibody; ATA: anti-Topoisomerase I; Ab: antibody; ^ap-values between RNAP and ATA; ^b: p-values between RNAP and ACA; yrs: mean years; n: number; SD: standard deviation; FVC: forced vital capacity; DLCO: diffusing Lung capacity for carbon monoxide

Supplementary Figure 1. Cumulative survival of SSc patients stratified by Antibody status.

